{"id":12922,"date":"2026-01-10T06:05:16","date_gmt":"2026-01-10T06:05:16","guid":{"rendered":"https:\/\/thegulfpress.com\/oncology-molecular-diagnostics-market-to-reach-usd-3-68-billion-with-2031-driven-by-rising-importance-of-precise-genomic-information-in-treatment-planning\/"},"modified":"2026-01-10T06:05:16","modified_gmt":"2026-01-10T06:05:16","slug":"oncology-molecular-diagnostics-market-to-reach-usd-3-68-billion-with-2031-driven-by-rising-importance-of-precise-genomic-information-in-treatment-planning","status":"publish","type":"post","link":"https:\/\/thegulfpress.com\/en\/oncology-molecular-diagnostics-market-to-reach-usd-3-68-billion-with-2031-driven-by-rising-importance-of-precise-genomic-information-in-treatment-planning\/","title":{"rendered":"Oncology Molecular Diagnostics Market to Reach USD 3.68 billion with 2031, Driven by Rising Importance of Precise Genomic Information in Treatment Planning"},"content":{"rendered":"


\n<\/p>\n

Mordor Intelligence has published a new report on<\/span><\/b>\u00a0Oncology Molecular Diagnostics Market<\/span><\/b>, offering a comprehensive analysis of trends, growth drivers, and future projections.<\/span><\/b>\u00a0<\/span><\/p>\n

Introduction:\u00a0<\/span><\/b>\u00a0<\/span><\/p>\n

Oncology Molecular Diagnostics Market<\/span><\/a>\u00a0size in 2026 is estimated at USD 4.13 billion, growing from 2025 value of USD 3.68 billion with 2031 projections showing USD 7.33 billion, growing at 12.18% CAGR over 2026-2031<\/span>, reflecting robust demand and steady oncology molecular diagnostics market growth. This growth is driven by increasing cancer incidence worldwide and the rising importance of precise genomic information in treatment planning. Patients, clinicians, and healthcare systems are placing greater emphasis on tests that help\u00a0determine\u00a0targeted treatment options,\u00a0monitor\u00a0disease progression, or detect minimal residual disease. As a result, the oncology molecular diagnostics market is gaining broader adoption across hospitals, reference laboratories, and decentralized care settings worldwide.\u00a0<\/span>\u00a0<\/span><\/p>\n

Key Trends<\/span><\/b>\u00a0<\/span><\/p>\n

The\u00a0oncology molecular diagnostics\u00a0marketanalysis\u00a0indicates several noteworthy trends influencing how clinicians and laboratories adopt and\u00a0utilize\u00a0testing sol<\/span>utions:<\/span>\u00a0<\/span><\/p>\n

    \n
  1. Liquid Biopsy Adoption and Companion Diagnostics<\/span><\/b><\/li>\n<\/ol>\n

    Non-invasive liquid biopsies continue to gain traction as alternatives or complements to traditional tissue biopsies, enabling repeated sampling for genomic monitoring without\u00a0additional\u00a0invasive procedures. Regulatory approvals of companion diagnostics tied to targeted therapies have supported broader clinical uptake.\u00a0<\/span>\u00a0<\/span><\/p>\n

      \n
    1. Integration of AI and Bioinformatics<\/span><\/b><\/li>\n<\/ol>\n

      Artificial intelligence and bioinformatics platforms are becoming more prevalent, helping laboratories interpret complex genomic data faster and with greater accuracy. These tools can automate variant calling and reduce turnaround times, boosting the appeal of comprehensive molecular profiling.\u00a0<\/span>\u00a0<\/span><\/p>\n

        \n
      1. Shift Toward Decentralized Testing<\/span><\/b><\/li>\n<\/ol>\n

        Point-of-care platforms and simplified molecular assays are enabling oncology testing beyond traditional central laboratories. Cartridge-based systems and ease-of-use features allow smaller clinics and community hospitals to\u00a0provide\u00a0molecular diagnostic insights more rapidly.\u00a0<\/span>\u00a0<\/span><\/p>\n

          \n
        1. Regional Growth Dynamics<\/span><\/b><\/li>\n<\/ol>\n

          Geographically, North America\u00a0remains\u00a0the largest contributor to the oncology molecular diagnostics market due to\u00a0established\u00a0healthcare infrastructure and reimbursement frameworks, while the Asia-Pacific region shows the fastest\u00a0oncology molecular diagnostics\u00a0marketgrowth\u00a0as national genomics programs expand and cancer testing demand increases.\u00a0<\/span>\u00a0<\/span><\/p>\n

          Market Segmentation\u00a0<\/span><\/b>\u00a0<\/span><\/p>\n

          The oncology molecular diagnostics market is structured around several essential segments, capturing product types, technologies, sample categories, end users, and geographies. This segmentation helps stakeholders understand where demand is strongest and how adoption patterns vary across clinical and regional contexts.<\/span>\u00a0<\/span><\/p>\n

          By Product Type<\/span><\/b>\u00a0<\/span><\/p>\n